RT Book, Section
A1 O’Connell, Mary Beth
A1 Borchert, Jill S.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1163299746
T1 Osteoporosis and Osteomalacia
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1163299746
RD 2023/06/05
AB Content  UpdateMay  8,  2019Romosozumab-aqqg  (Evenity)  Approved  for  Treatment  of  Osteoporosis:  In  April  2019,  the  US.  Food  and  Drug  Administration  (FDA)  approved  romosozumab-apqg  to  treat  osteoporosis  in  postmenopausal  women  at  high  risk  of  fracture.  The  monoclonal  antibody  blocks  the  effects  of  the  protein  sclerostin  and  primarily  stimulates  new  bone  formation,  although  it  also  has  antiresorptive  activity.  Two  phase  3  clinical  trials  demonstrated  reductions  in  bone  fractures  after  12  months  when  compared  to  placebo  and  to  oral  alendronate  70  mg  daily.  The  labeling  contains  a  boxed  warning  that  it  may  increase  the  risk  of  MI,  stroke  and  cardiovascular  death,  which  may  limit  use  of  the  drug  because  the  target  population  is  older  women  who  may  be  at  higher  cardiovascular  risk.  Romosozumab-apqg  offers  a  novel  anabolic  treatment  strategy  for  women  who  are  at  high  risk  of  osteoporotic  fracture  but  is  expensive,  with  a  U.S.  list  price  reported  to  be  $21,900  for  a  full  12-month  course  of  injections.